Nancy Bouloute
Family · North Miami, FLNPI 1265984991
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 24.5% of the total. Reporting peaked in 2023 at $2,542 and has fallen 64.5% since, to $901 in 2025. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $39.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- Johnson & Johnson$897
- Boehringer Ingelheim$794
- GSK$656
- Lilly USA, LLC$434
- plus $2K from 22 others
What the payments were for
- Travel & lodging$2443%
- Food & beverage$7,32696%
- Education$941%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $1,877 |
| AstraZeneca | 19 | $1,104 |
| Johnson & Johnson | 12 | $897 |
| Boehringer Ingelheim | 14 | $794 |
| GSK | 13 | $656 |
| Lilly USA, LLC | 20 | $434 |
| Exact Sciences | 16 | $360 |
| Pfizer | 7 | $198 |
| Novo Nordisk | 9 | $162 |
| Bayer | 2 | $139 |
| Amgen | 2 | $132 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $130 |
| Abbott | 1 | $125 |
| Astellas Pharma US Inc | 2 | $108 |
| Sanofi-aventis U.S. LLC | 6 | $102 |
| Shield Therapeutics Inc | 2 | $84 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $79 |
| Gilead | 2 | $50 |
| Novartis | 2 | $37 |
| Phadia US Inc. | 2 | $34 |
| Almatica Pharma LLC | 2 | $27 |
| Angiodynamics, Inc. | 1 | $27 |
| Tactile Systems Technology Inc | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Insightec,inc | 1 | $17 |
| Seqirus USA Inc | 1 | $15 |
| Alvogen Inc | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,663 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 40 | $53,830 |
| JardianceEmpagliflozin | 28 | $43,605 |
| FarxigaDapagliflozin Propanediol | 37 | $37,794 |
| LinzessLinaclotide | 29 | $36,643 |
| EliquisApixaban | 19 | $29,142 |
| XareltoRivaroxaban | 19 | $27,438 |
| MounjaroTirzepatide | 20 | $27,173 |
| RybelsusSemaglutide | 14 | $23,631 |
| InvokametCanagliflozin/Metformin Hcl | 13 | $21,109 |
| OzempicSemaglutide | 16 | $15,415 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $4,376 |
| Megestrol Acetate | 11 | $2,264 |
| Atorvastatin Calcium | 241 | $2,034 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $2,002 |
| Nifedipine ErNifedipine | 57 | $1,643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto, Invokamet | $897 | $48,54732 claims |
| Boehringer IngelheimJardiance | $794 | $43,60528 claims |
| Novo NordiskRybelsus, Ozempic | $162 | $39,04630 claims |
| AstraZenecaFarxiga | $1,104 | $37,79437 claims |
| AbbVieLinzess | $1,877 | $36,64329 claims |
| PfizerEliquis | $198 | $29,14219 claims |
| Lilly USA, LLCMounjaro | $434 | $27,17320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in North Miami
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.